shortage

Ozempic Wegovy

Pharma

Novo asks FDA to prevent compounders from making GLP-1 knockoffs

Novo Nordisk has asked the FDA to prevent compounders from manufacturing copycat versions of its diabetes and obesity treatments Ozempic and Wegovy.

Kevin Dunleavy Oct 23, 2024 2:29pm

FDA Building 2

Pfizer, Teva running short on COVID-19 hopeful azithromycin

Apr 23, 2020 9:55am

GSK

Shingrix shortage to persist 'throughout 2019'

Dec 11, 2018 9:08am